Olaratumab Package Insert

Medical Department Procedure Manual - Home - AvMed
Olaratumab (Lartruvo) is a platelet-derived growth factor receptor alpha blocking antibody indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is ... Document Retrieval

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TALTZ safely and effectively. See full prescribing information for ... Get Document

HIGHLIGHTS OF PRESCRIBING INFORMATION ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LARTRUVOsafely and effectively. See full prescribing information forLARTRUVO. LARTRUVO(olaratumab)injection, for intravenous use Initial U.S. Approval: 2016 ... Visit Document

Reference ID: 4001156
LARTRUVO (olaratumab) injection, for intravenous use Initial U.S. Approval: 2016----- INDICATOI NS AND USAGE ----- LARTRUVO™ is a platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody indicated, in combination with ... Fetch Here

CLINICAL REVIEW - Fda.gov
Incorporated into the Yondelis® package insert. This recommendation is based on the review pazopanib, olaratumab, and eribulin mesylate. Of these approved therapies, only trabectedin has been ... Get Doc

KY Medicaid Proposed Formulary Changes - CareSource
T1/2 at the doses recommended by the package insert (15 mg/kg) was a range of 6.04-9.38 days after the first dose, and 8.25 days after multiple doses. 5. Efficacy: Trial Design/ Population Groups Outcomes Results Two part open label trial with 15 patients in the phase 1b portion and 129 patients in the phase 2 portion 1 15 patients studying ... Access This Document

Nicole McCullom, Pharm.D. - Oncology
Lartruvo™ (olaratumab) in combination with doxorubicin was studied in a randomized, phase 2 clinical • Lartruvo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2017. • Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin ... Access Document

Isatuximab - Wikipedia
Isatuximab is a monoclonal antibody (mAb) designed for the treatment of cancer. It was developed by ImmunoGen and Sanofi-Aventis with the development name SAR-650984 . It was given orphan drug status for multiple myeloma by the FDA in December 2016. ... Read Article

HIGHLIGHTS OF PRESCRIBING INFORMATION ZINPLAVAsafely And ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ZINPLAVAsafely and effectively. See full prescribing information ... Fetch Full Source

Lartruvo (olaratumab) - Magellan Provider
LARTRUVO (olaratumab) Prior Auth Criteria Proprietary Information. Restricted Access – Do not disseminate or copy without approval. ©2018, Magellan Rx Management 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for olaratumab. National Comprehensive Cancer Network, 2018. The ... Retrieve Full Source

PATIENT INFORMATION A HALAVEN (HAL-ih-ven) HALAVEN (eribulin ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HALAVEN safely and HALAVEN® (eribulin mesylate) injection, for intravenous use See 17 for PATIENT COUNSELING INFORMATION and FDA-approved Patient Labeling ... Get Document

PACKAGE INSERT (ENGLISH) - Zoetis
Reproduction. An environmental infestation of fleas may persist for a short time after beginning treatment with REVOLUTION because of the emergence of adult fleas from pre-existing pupae. However, large reductions in flea infestations are observable after just one monthly treatment. ... Retrieve Document

5.21.91 Lartruvo (olaratumab) 3 17 17 EA - FEP Blue
1. Lartruvo [package insert]. Indianapolis, IN: Eli Lilly and Company; October 2016. Policy History Date Action November 2016 Addition to PA March 2017 Annual Review Keywords This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 17, 2017 and is effective on April 1, 2017. _____ ... Access This Document

Label - Food And Drug Administration
• Gently invert the bag to mix the diluted solution and avoid foaming or excessive shearing. • Inspect the solution to ensure it is clear, colorless, and free of visible particles. ... View Doc

LARTRUVO (olaratumab) RATIONALE FOR INCLUSION IN PA PROGRAM
(olaratumab) Prior approval is required to ensure the safe, clinically appropriate and cost effective use of Lartruvo while maintaining optimal therapeutic outcomes. References . 1. Lartruvo [package insert]. Indianapolis, IN: Eli Lilly and Company; February 2017. ... Read More

Antineoplastic Agents - BMC HealthNet Plan
Keytruda® (package insert). Whitehouse (NJ): Merck; Jan 2015. + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. ... Read Document

TOPA 2017 New Drug Update - Toparx.org
Lartruvo [package insert].Indianapolis, IN:Eli Lilly and Company;2017 Olaratumab • Dosage Adjustments for Toxicity Hematologic Neutropenic fever/infection or grade 4 neutropenia lasting longer than 1 week Withhold olaratumab until ANC is ≥ 1,000/mm3, then resume with dose permanently reduced to 12 mg/kg ... Get Document

HIGHLIGHTS OF PRESCRIBING INFORMATION The Dose For RA In ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RITUXAN safely and effectively. See full prescribing information for ... Fetch Doc

NEW DRUG UPDATE 2017 - Ncop.memberlodge.org
Olaratumab - dosing •Olaratumab 15 mg/kg IV over 60 minutes on days 1 and 8 of a 21 day cycle with •Doxorubicin* 75 mg/m2 IV on day 1 •Olaratumab to be given with doxorubicin for the first 8 cycles, then –As single agent until progressive disease or unacceptable toxicity. Lartruvo package insert. Eli Lilly and Company. 2016, *Tap WD. ... Return Document

HIGHLIGHTS OF PRESCRIBING INFORMATION Uveitis (UV) (1.10 ...
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for ... Fetch Full Source